Skip to main content

#152087

MCF7/TAMR-7 Cell line

Cat. #152087

MCF7/TAMR-7 Cell line

Cat. #: 152087

Sub-type: Continuous

Unit size: 1x10^6 cells / vial

Availability: 10-12 weeks

Organism: Human

Tissue: Breast

Disease: Cancer

Model: Tumour line

£800.00

This fee is applicable only for non-profit organisations. If you are a for-profit organisation or a researcher working on commercially-sponsored academic research, you will need to contact our licensing team for a commercial use license.

Contributor

Inventor: Anne Lykkesfeldt

Institute: Danish Cancer Society, Denmark

Tool Details
Target Details
Applications
Handling
Related Tools
References

Tool Details

*FOR RESEARCH USE ONLY (for other uses, please contact the licensing team)

  • Name: MCF7/TAMR-7 Cell line
  • Alternate name: MCF-7/TAMR-7; TAMR-7
  • Cancer: Breast cancer
  • Cancers detailed: Breast cancer;Tamoxifen resistant
  • Research fields: Cancer;Drug development
  • Tool sub type: Continuous
  • Parental cell: MCF7 S0.5
  • Organism: Human
  • Gender: Female
  • Tissue: Breast
  • Disease: Cancer
  • Model: Tumour line
  • Conditional: Yes
  • Description: MCF7/TAMR-7 cell line is a stable tamoxifen-resistant subline. The cell line has been established in tissue culture after long term treatment with 1uM tamoxifen. Tamoxifen (Nolvadex) is a widely used drug for hormone-dependent cancer. Tamoxifen resistance (either primary or acquired) makes oestrogen receptor-positive breast cancer much more difficult to treat. This cell line was produced as an adaptation of an original cell line (MCF7/S0.5), as a model cell system to study the effects of tamoxifen resistant cancer growth. MCF7/TAMR-7 cells are oestrogen receptor positive and progesterone receptor negative. Previous applications of this cell line include treatment with steroidal antiestrogens. MCF7/TAMR-7 enables identification of new hormone therapies and greater understanding of the signalling pathways/methods behind tamoxifen resistance.
  • Application: Investigate signalling pathways involved in tamoxifen resistance
  • Production details: The parental cell line for the MCF7/TAMR-7 cells is MCF7/S0.5, which was adapted to grow at low serum concentration in order to study the effect of estradiol and tamoxifen. MCF7/TAMR-7 has been established from a clone of cells that survived long term treatment with 1 uM tamoxifen. Tamoxifen-resistant cells are passaged continuously in presence of 1 uM tamoxifen, which is lethal for the parental MCF7/S0.5 cell line.
  • Recommended controls: MCF7-S0.5 parental line
  • Cellosaurus id: 1D43

Target Details

  • Target: Oestrogen receptor

Applications

  • Application: Investigate signalling pathways involved in tamoxifen resistance
  • Application notes: MCF7/TAMR-7 cells are oestrogen receptor positive and progesterone receptor negative. MCF7/TAMR-7 cells are growth inhibited by the pure antioestrogen fulvestrant. The oestrogen receptor is a major driver of growth of MCF7/TAMR-7 cell. The TAMR lines were established from the MCF7/S0.5 cell line, which was adapted to grow with 0.5% fetal calf serum in phenol red containing DMEM/F12 medium. Treatment with tamoxifen was started in passage 351. Few colonies of cells survived the treatment and a...

Handling

  • Format: Frozen
  • Growth medium: Phenol red-free DMEM:Ham's F-12 containing 1% fetal bovine serum, 2 mM Glutamax and 6 ng/ml insulin. To maintain high-level resistance, medium was supplemented with Tamoxifen (1 uM).
  • Temperature: 37° C
  • Atmosphere: 5% CO2
  • Unit size: 1x10^6 cells / vial
  • Shipping conditions: Dry ice

Related Tools

  • Related tools: MCF7/S0.5 Cell Line

References

  • Hole et al. 2015. Int J Oncol. 46(4):1481-1490. PMID: 25625755.
  • Elias et al. 2015. Oncogene. 34(15):1919-1927. PMID: 24882577.
  • Pedersen et al. 2014. Int J Oncol. 45(5):2167-2175. PMID: 25175082.
  • Lundqvist et al. 2014. Steroids. 85:30-35. PMID: 24747771.
  • Thrane et al. 2013. Breast Cancer Res Treat. 139(1):71-80. PMID: 23609470.
  • Larsen et al. 2012. Int J Oncol. 41(5):1863-1870. PMID: 22961366.
  • Frankel et al. 2007. Breast Cancer Res Treat. 104(2):165-179. PMID: 17061041.
  • Berstein et al. 2003. Endocr Relat Cancer. 10(2):267-277. PMID: 12790788.

Tool enquiry

Please ensure you use your organisation email address rather than personal where possible, as this helps us locate your organisation in our system faster.

Please note we may take up to three days to respond to your enquiry.

CancerTools.org uses the contact information provided to respond to you about our research tools and service. For more information please review our privacy policy.